Venetoclax and ibrutinib are two relatively new drugs being used for the treatment of chronic lymphocytic leukemia (CLL), and although studies are suggesting them to be more effective than conventional chemotherapies in certain contexts, concerns remain surrounding their cost, particularly if used in combination. However, as explained here by John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, an effective combination therapy of a shorter duration may be cheaper than years of an inferior treatment; researchers must find the clinical contexts where investing in these treatments will bring about the most benefit for patients. This interview was recorded the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA.
Financial benefit of combining two expensive drugs for CLL
